We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000547:SZSEAddsino Co., Ltd. Analysis

Data as of 2026-03-16 - not real-time

CN¥31.87

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Addsino Co., Ltd. is trading around 31.87 CNY, well above its DCF‑derived fair value of ~4 CNY, implying a severe pricing disconnect. The forward P/E of 77.7× dwarfs the industry average of 34.3×, while the price‑to‑book sits at 10.8×, further underscoring an overvalued stance. Technical signals are mixed: the MACD line remains just above its signal, producing a modest bullish histogram, and the RSI sits near the neutral 54 level, suggesting limited upside momentum. Fundamental health is weak, with negative gross (‑13.8%) and operating margins, a trailing EPS of ‑1.01, and a high debt‑to‑equity ratio exceeding 17, raising concerns about profitability and balance‑sheet resilience.
Liquidity appears adequate given stable, high trading volumes, but the company faces heightened sector and regulatory risks tied to China’s defense‑related technology space, alongside geographic concentration risk. The extreme “Greed” reading on the fear‑greed index reflects market optimism that may be unjustified given the stark valuation gap and deteriorating earnings profile. Investors should weigh the modest technical bullishness against the fundamental overvaluation and risk backdrop before making a call.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Technical MACD bullish crossover but weak momentum
  • Severe overvaluation relative to DCF and peers
  • Stable liquidity mitigating immediate price pressure

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Continued earnings deficits and negative margins
  • Persistently high forward P/E versus industry
  • Regulatory scrutiny in China’s defense‑tech sector

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Fundamental deterioration with negative EPS and high debt
  • Valuation gap unlikely to close without structural turnaround
  • Elevated sector and regulatory risks in a geopolitically sensitive market

Key Metrics & Analysis

Financial Health

Revenue Growth209.20%
Profit Margin-67.50%
P/E Ratio77.7
ROE-27.20%
ROA-7.74%
Debt/Equity17.37
P/B Ratio10.8
Op. Cash FlowCN¥333.4M
Free Cash FlowCN¥164.4M
Industry P/E34.3

Technical Analysis

TrendNeutral
RSI54.3
SupportCN¥26.86
ResistanceCN¥34.30
MA 20CN¥30.54
MA 50CN¥30.75
MA 200CN¥15.09
MACDBullish
VolumeStable
Fear & Greed Index78.29

Valuation

Fair ValueCN¥4.03
GradeOvervalued
TypeValue

Risk Assessment

Beta0.19
Volatility77.68%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.